Collaboration extension through 2029 accelerates access to MRD technology across four major cancer types Colorectal cancer affects over 150,000 new patients in the U.S. annually, with many patients ...
We recently compiled a list of the Top 12 AI Stock News and Ratings Dominating Wall Street. In this article, we are going to take a look at where Tempus AI, Inc (NASDAQ:TEM) stands against the other ...
Personalis (PSNL) and Tempus AI (TEM) announced that the companies have expanded their commercial relationship.The companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD ...
FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (PSNL) and Tempus AI, Inc. (TEM) announced today that the companies have expanded their commercial relationship. The companies agreed in November ...
Zacks Investment Research on MSN
How Tempus AI is advancing toward regulatory pricing catch-up
Tempus AI’s TEM reimbursement showed modest sequential improvement in the third quarter of 2025, though average blended reimbursement per test continues to lag peers by a meaningful margin. The ...
Tempus AI, Inc (NASDAQ:TEM) is a healthcare technology company that provides AI-enabled precision medicine solutions. On December 16, the company announced that it has expanded its relationship with ...
Tempus AI TEM is leaning into a dual-engine model: a fast-growing Genomics franchise and a scaling data business powered by an expanding AI toolkit. The third quarter of 2025 marked a turn to non-GAAP ...
Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) announced today that the companies have expanded their commercial relationship. The companies agreed in November 2023 to collaborate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback